最終更新日:2022/12/24

Recently, mogamulizumab (anti-CCR4 antibody, Kyowa Hakko Kirin) and obinutuzumab (anti-CD20 antibody, Genentech/Roche) with depleted core fucoses have been approved for marketing, and several glycoengineered antibodies are in clinical studies and are being developed as next generation therapeutic monoclonal antibodies.

編集履歴(0)

Sentence quizzes to help you learn to read

編集履歴(0)

ログイン / 新規登録

 

アプリをダウンロード!
DiQt

DiQt(ディクト)

無料

★★★★★★★★★★